Your browser doesn't support javascript.
loading
Safety intervention for improving functioning in suicidal attempters (STRONG): A secondary prevention study. Study rationale and research protocol.
Roberto, Natalia; Vazquez, Mireia; Radua, Joaquim; Pariente, Jose Carlos; Muñoz-Moreno, Emma; Laredo, Carlos; Bracco, Lorenzo; Fernández, Tábatha; Martín-Parra, Sara; Martínez-Aran, Anabel; Sánchez-Moreno, Jose; Saiz, Pilar; Ruiz-Veguilla, Miguel; Borras, Roger; Toll, Alba; Elices, Matilde; Brambilla, Paolo; Courtet, Philippe; Perez-Solà, Víctor; Vieta, Eduard; Grande, Iria.
Afiliação
  • Roberto N; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. Villarroel, 170, 08036 Barcelona, Spain; Institute of Neurosciences (UBNeuro), P. de la Vall d'Hebron, 171, 08035 Ba
  • Vazquez M; Departamento de Psicología Clínica i Psiquiatría, Instituto de Neurociencias, Hospital Clínico de Barcelona, C. Casanova, 140, 08036 Barcelona, Spain.
  • Radua J; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. Villarroel, 170, 08036 Barcelona, Spain; Centro de Investigación Biomédica en Red de S
  • Pariente JC; Magnetic Resonance Imaging Core Facility, IDIBAPS (Institut d'Investigació Agustí Pi i Sunyer), Barcelona, Spain.
  • Muñoz-Moreno E; Magnetic Resonance Imaging Core Facility, IDIBAPS (Institut d'Investigació Agustí Pi i Sunyer), Barcelona, Spain.
  • Laredo C; Magnetic Resonance Imaging Core Facility, IDIBAPS (Institut d'Investigació Agustí Pi i Sunyer), Barcelona, Spain.
  • Bracco L; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Fernández T; Departamento de Psicología Clínica i Psiquiatría, Instituto de Neurociencias, Hospital Clínico de Barcelona, C. Casanova, 140, 08036 Barcelona, Spain.
  • Martín-Parra S; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Departament de Psicologia Clínica i Psicobiologia, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036 Barcelona, Spain.
  • Martínez-Aran A; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C. Villarroel, 170, 08036 Barcelona, Spain; Institute of Neurosciences (UBNeuro), P. de la Vall d'Hebron, 171, 08035 Ba
  • Sánchez-Moreno J; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August
  • Saiz P; Department of Psychiatry, University of Oviedo, Oviedo, Spain; Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain; Instituto de Neurociencias del Principado de Asturi
  • Ruiz-Veguilla M; Virgen del Rocio University Hospital, University of Sevilla/IBiS/CIBERSAM, Seville, Spain.
  • Borras R; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain; Arrhythmia Section, Cardiology Department, Thorax Institute, Hospital Clínic and IDIBAPS (Institut d'Investigació Agustí Pi i Sunyer), University of Barcelona, C. Villarroel, 170, 08036
  • Toll A; Institute Mar of Medical Research, IMIM, Barcelona, Spain.
  • Elices M; Institut d'Investigació Biomèdica-Sant Pau (IIB-NTPAU), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Institute Mar of Medical Research, IMIM, Barcelona, Spain.
  • Brambilla P; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Courtet P; Department of Emergency Psychiatry and Acute Care, Centre Hospitalier Universitaire Montpellier, University of Montpellier, Montpellier, France.
  • Perez-Solà V; Institut d'Investigació Biomèdica-Sant Pau (IIB-NTPAU), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Institute Mar of Medical Research, IMIM, Barcelona, Spain.
  • Vieta E; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August
  • Grande I; Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, C. Villarroel, 170, 08036 Barcelona, Spain; Departament de Medicina, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), C. Casanova, 143, 08036 Barcelona, Spain; Institut d'Investigacions Biomèdiques August
Article em En | MEDLINE | ID: mdl-38591829
ABSTRACT

BACKGROUND:

Suicide is one of the most largely preventable causes of death worldwide. The aim of the STRONG study is to assess the effectiveness of a specific intervention (an extended Safety Planning Intervention) called iFightDepression-SURVIVE (iFD-S) in suicidal attempters by changes in psychosocial functioning. As secondary outcomes, quality of life, cognitive performance, clinical state and neuroimaging correlates will be considered.

OBJECTIVE:

To describe the rationale and design of the STRONG study, an extension of the SURVIVE study, a national multicenter cohort about on prevention in suicidal attempters.

METHODS:

The STRONG study is a two-year clinical trial. A total sample of 60 patients will be randomly allocated to two arms a group will receive a iFD-S and treatment as usual (TAU) (n=30 treatment group), while another group will exclusively receive TAU (n=30 control group). There will be three study points baseline; 3-month; and 6-month follow-up assessments, all of which will include rater-blinded evaluation of psychosocial functioning, quality of life, clinical state, cognitive performance and neuroimaging acquisition.

RESULTS:

It is expected to obtain data on the efficacy of iFD-S in patients who have committed a suicide attempt.

CONCLUSION:

Results will provide insight into the effectiveness of IFD-S in suicidal attempters with respect to improvements in psychosocial functioning, quality of life, cognition, and neuroimaging correlates. CLINICAL TRIALS ID NCT05655390.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article